Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study

Acta Ophthalmologica Scandinavica

Volumn 79, Issue 6, 2001, Pages 567-571

  Larsson, L I ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Circadian variation; Diurnal; Intraocular pressure; Latanoprost; Nocturnal

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; LATANOPROST; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN EXPERIMENT; HYPEREMIA; INTRAOCULAR PRESSURE; MALE; MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TIME; VOLUNTEER;

ADULT; ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC;

EID: 0035214331     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.2001.790604.x     Document Type: Article

References (33)

1. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol
2. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening and morning. A comparison with timolol
3. Latanoprost. Experience of 2-year treatment in Scandinavia
4. The effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertension
5. Glaucoma: A physiologic perspective with Darwanian overtones
6. The impact of intraocular pressure on venous outflow from the globe: A hypothesis regarding IOP-dependent vascular damage in normal-tension and hypertensive glaucoma
7. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture
8. 24-Hour (nyctohemeral) and sleep-related variations of intraocular pressure in healthy white individuals
9. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States
10. Latanoprost, a prostaglandin analog, for glaucoma treatment. Efficacy and safety after one year of treatment in 198 patients
11. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humor protein concentration in glaucoma patients. A randomized, double-masked, comparison with timolol 0.5%
12. The significance of the diurnal tension variations in normal and glaucomatous eyes
13. Twenty-four hourly variations of the aqueous flow
14. Diurnal variation of intraocular pressure and the overriding effects of sleep
15. Ambulatory blood pressure monitoring in glaucoma
16. 2α-isopropyl ester analogues for glaucoma treatment
17. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension of primary open-angle glaucoma
18. 2α analogue reduces the intraocular pressure (IOP) in human volunteers during day and night
19. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma
20. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma
21. Occult intraocular pressure elevation and optic disc cup assymmetry: Sleep posture may be a risk factor
22. Aqueous flow in open-angle glaucoma
23. Circadian rhythm of intraocular pressure
24. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans
25. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study
26. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens
27. 2α analogue
28. 2α analogue, on aqueous humor dynamics in human eyes
29. A six-month, randomized, double-masked study comparing latanoprost to timolol in open-angle glaucoma and ocular hypertension
30. Latanoprost - Two years' experience of its use in the United Kingdom
31. Individual variability in the diurnal intraocular pressure curve
32. Circadian variations in intraocular pressure
33. 2α analogue, after topical application in normal and ocular hypertensive human eyes